Entities / Company
BioXconomy.
B2B media site for the global bio-based economy
- Reports this week
- 0
- Active events
- 0
- Connections
- 8
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
BioXconomy provided Q&A details regarding regulatory agency interactions involving the FDA.Some support1 report
-
Industry invests in data infrastructure to improve patient outcomes, involving BioXconomy.Some support1 report1 development inside
-
BioXconomy reports figures provided by the BioIndustry Association (BIA), which is based in London.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around BioXconomy this week
News at the entities that move BioXconomy most-
MCU OperationalCleaner moved from Netflix to Apple TV, while Jackson stars as Nick Fury in the MCU, and Paramount released a new spin-off.Moves BioXconomy
-
FDA StructuralNRx Pharmaceuticals is seeking regulatory approval from the FDA for its drug candidates, NRX-100 and NRX-101.Moves BioXconomy
-
Reed Smith OperationalThe Anti-Defamation League and Reed Smith filed a civil rights complaint together.Moves BioXconomy
-
Securities and Exchange Commission Mentioned togetherAnthropic filed an S-1 with the SEC while competing with Google in the race to market via IPO.Moves BioXconomy
Connections
The 5 strongest of 8, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
BioXconomy operates within the regulatory framework established by the FDA, relying on its processes for market viability.
-
BioIndustry Association Structural
BioXconomy reports figures provided by the BioIndustry Association.
-
MCU Operational
BioXconomy discusses how the MCU provides fictional scenarios that ground serious molecular biology crises.
-
Reed Smith Operational
A Reed Smith partner engaged in a conversation with BioXconomy.
-
Securities and Exchange Commission Mentioned together
BioXconomy reports on the regulatory oversight implications of the Securities and Exchange Commission.